Source: CureToday articles
The biologics license application seeks potential approval of a Darzalex Faspro-based regimen for newly diagnosed multiple myeloma ineligible for transplant.
Recent Content
- Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
- Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma
- Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy
- High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
- CAR-T cell therapy in Multiple Myeloma: current status and future challenges
- Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma
- Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
- Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
- A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
- Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma